This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Mortality in patients with dementia treated with atypical antipsychotics (olanzapine, quetiapine and ziprasidone)

Authors

Martínez Martínez, L., Olivera Fernández, M. R., Piñeiro Corrales, G.

Journal

Farmacia Hospitalaria: Órgano Oficial De Expresión Científica De La Sociedad Española De Farmacia Hospitalaria, Volume: 33, No.: 4, Pages.: 224-228

Year of Publication

2009

Abstract

Introduction: The atypical antipsychotics (AA) quetiapine, olanzapine and ziprasidone are used to treat behavioural disorders associated with dementia. This indication does not appear on their technical sheet. The object of this study is to analyse the relationship of these treatments with mortality and other factors.; Method: Retrospective study from March 2005 to July 2007 of AA treatments requested as compassionate use. We collected information on mortality, age, history of heart disease or cerebrovascular disease, and duration and number of concomitant treatments per patient.; Results: 289 patients were studied. Mortality was 31.1%. A higher mortality rate was shown for patients with a history of heart disease and in those who used olanzapine. Quetiapine was the most commonly prescribed antipsychotic drug.; Conclusions: The use of AA in the elderly could have risks that outweigh the benefits. When prescribing these drugs for at-risk patients, one should consider their safety warnings and the individual case of each patient. According to our data, olanzapine seems to be associated with a higher risk than quetiapine and ziprasidone.;

Keywords

adverse effects, aged, aged, 80 and over, and, antipsychotic agents, benzodiazepines, chemically induced, compassionate use trials, dementia, dibenzothiazepines, drug therapy, female, humans, male, mental disorders, middle aged, mortality, olanzapine, piperazines, quetiapine, retrospective studies, thiazoles, ziprasidone

Countries of Study

Spain

Types of Dementia

Dementia (general / unspecified)

Types of Study

Cohort Study

Type of Outcomes

Carer Burden (instruments measuring burden)

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Antipsychotics and antidepressants